IMU 4.00% 4.8¢ imugene limited

Ann: Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia, page-31

  1. 6,757 Posts.
    lightbulb Created with Sketch. 4450
    If say the trial outcome for both the mono and combo turns out to be the same but better than Keytruda only results, then this Vaxinia will render Keytruda obsolete. If that should come to pass, Merck will act immediately!
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.